• 1
    Williams CS,Mann M,DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 1999; 18: 79087916.
  • 2
    O'Byrne KJ,Dalgleish AG,Browning MJ,Steward WP,Harris AL. The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer. 2000; 36: 151169.
  • 3
    Tsujii M,Kawano S,DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA. 1997; 94: 33363340.
  • 4
    Uefuji K,Ichikura T,Mochizuki H. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res. 2000; 6: 135138.
  • 5
    Cardillo I,Spugnini EP,Verdina A,Galati R,Citro G,Baldi A. Cox and mesothelioma, an overview. Histol Histopathol. 2005; 20: 12671274.
  • 6
    Spugnini EP,Porrello A,Citro G,Baldi A. Cox-2 overexpression in canine tumors, potential therapeutic targets in oncology. Histol Histopathol. 2005; 20: 13091312.
  • 7
    O'Banion MK,Winn VD,Young DA. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci USA. 1992; 89: 48884892.
  • 8
    Marrogi A,Pass HI,Khan M,Metheny-Barlow LJ,Harris CC,Gerwin BI. Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): in vitro antiproliferative effects of a COX-2 inhibitor. Cancer Res. 2000; 60: 36963700.
  • 9
    Edwards JG,Faux SP,Plummer SM, et al. Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. Clin Cancer Res. 2002; 8: 18571862.
  • 10
    Baldi A,Di Santini D,Vasaturo F, et al. Prognostic significance of COX-2 and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma. Thorax. 2004; 59: 428433.
  • 11
    Mossman BT,Kamp DW,Weitzman SA. Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers. Cancer Invest. 1996; 14: 466480.
  • 12
    Kamp DW,Weitzman SA. The molecular basis of asbestos induced lung injury. Thorax. 1999; 54: 638652.
  • 13
    Mossman BT,Churg A. Mechanisms in the pathogenesis of asbestosis and silicosis. Am J Respir Crit Care Med. 1998; 157: 16661680.
  • 14
    Baldi A,Groeger AM,Esposito V, et al. Expression of p21 in SV40 large T antigen positive human pleural mesothelioma: relationship with survival. Thorax. 2002; 57: 353356.
  • 15
    Spugnini EP,Campioni M,D'Avino A,Caruso G,Citro G,Baldi A. Cell-cycle molecules in mesothelioma, an overview. J Exp Clin Cancer Res. 2007; 26: 515521.
  • 16
    Spugnini EP,Bosari S,Citro G,Lorenzon I,Cognetti F,Baldi A. Human malignant mesothelioma: molecular mechanisms of pathogenesis and progression. Int J Biochem Cell Biol. 2006; 38: 20002004.
  • 17
    Vane JR,Mitchell JA,Appleton I, et al. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci USA. 1994; 91: 20462050.
  • 18
    Ambs S,Hussain SP,Marrogi AJ,Harris CC. Cancer-prone oxyradical overload disease. IARC Sci Publ. 1999; 150: 295302.
  • 19
    Sachs AB. Messenger RNA degradation in eukaryotes. Cell. 1993; 74: 413421.
  • 20
    Dixon DA,Kaplan CD,McIntyre TM,Zimmerman GA,Prescott SM. Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3′-untranslated region. JBiol Chem. 2000; 275: 1175011757.
  • 21
    Sheng H,Shao J,Dixon DA, et al. Transforming growth factor-β1 enhances Ha-rasinduced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J Biol Chem. 2000; 275: 66286635.
  • 22
    Good PJ. The role of elav-like genes, a conserved family encoding RNA binding proteins, in growth and development. Semin Cell Dev Biol. 1998; 8: 557584.
  • 23
    Dixon DA,Tolley ND,King PH, et al. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J Clin Invest. 2001; 108: 16571665.
  • 24
    Sengupta S,Jang BC,Wu MT,Paik JH,Furneaux H,Hla T. The RNA-binding protein HuR regulates the expression of cyclooxygenase-2. J Biol Chem. 2003; 278: 2522725233.
  • 25
    Subbaramaiah K,Marmao TP,Dixon DA,Dannenberg AJ. Regulation of cyclooxygenase-2 mRNA stability by taxanes. Evidence for involvement of p38, MAPKAPK-2 and HuR. J Biol Chem. 2003; 278: 3763737647.
  • 26
    Cok SJ,Acton SJ,Morrison AR. The proximal region of the 3′-untranslated region of cyclooxygenase-2 is recognized by a multimeric protein complex containing HuR, TIA-1, TIAR and the heterogeneous nuclear ribonucleoprotein U. J Biol Chem. 2003; 278: 3615736162.
  • 27
    Brennan CM,Steitz JA. HuR and mRNA stability. Cell Mol Life Sci. 2001; 58: 266277.
  • 28
    Denkert C,Weichert W,Winzer KJ, et al. Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma. Clin Cancer Res. 2004; 10: 55805586.
  • 29
    Denkert C,Koch I,von Keyserlingk N, et al. Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2. Mod Pathol. 2006; 19: 12611269.
  • 30
    Kaplan EL,Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 31
    Peto R,Pike MC,Armitage P, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. Br J Cancer. 1977; 35: 139.
  • 32
    Peto J,Decarli A,La Vecchia C,Levi F,Negri E. The European mesothelioma epidemic. Br J Cancer. 1999; 79: 666672.
  • 33
    Curran D,Sahmoud T,Therasse P,van Meerbeeck J,Postmus PE,Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998; 16: 145152.
  • 34
    Weder W,Kestenholz P,Taverna C, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol. 2004; 22: 34513457.
  • 35
    Vogelzang NJ.Rusthoven JJ,Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003; 21: 26362644.
  • 36
    Van Meerbeeck JP,Gaafar R,Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005; 23: 68816889.
  • 37
    Weder W,Stahel RA,Bernhard J, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol. 2007; 18: 11961202.
  • 38
    Lopez de Silanes I,Lal A,Gorospe M. HuR, post-transcriptional paths to malignancy. RNA Biol. 2005; 2: e11e13.
  • 39
    Spugnini EP,Cardillo I,Verdina A, et al. Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma. Clin Cancer Res. 2006; 12: 61336143.
  • 40
    Spugnini EP,Crispi S,Scarabello A,Caruso G,Citro G,Baldi A. Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations [serial online]. J Exp Clin Cancer Res. 2008; 27: 6.
  • 41
    Verdina A,Cardillo I,Nebbioso A, et al. Effects of piroxicam and cisplatin on mesothelioma cell growth and viability [serial online]. J Transl Med. 2008; 6: 27.
  • 42
    Solomon SD,McMurray JJ,Pfeffer MA, et al;Adenoma Prevention with Celecoxib (APC) Study Investigators. Risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005; 352: 10711080.
  • 43
    Bresalier RS,Sandler RS,Quan H, et al. Adenomatous polyp prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005; 352: 10921102.